Список проголосовавших за комментарий " Sector Summary: The Healthcare sector (+0.07%) is trading slightly today, outperforming the S&P 500 (-0.06%)<strong>General Commentary:</strong> Tonix Pharma (TNXP) shares are up more than 40% after initially opening up ~80%. The co filed a press release this morning that it was presenting presenting at The MicroCap Conference on April 4, 2017 in NYC. The interim analysis of the HONOR study is expected in the first half of 2018 and topline results are expected in the second half of 2018. The co announced yesterday before the market opened that it enrolled its first participant in the Phase 3 HONOR study of TNX-102 SL 5.6 mg, for the<br/> treatment of PTSD as well.<br/> <br/> <strong><span style="color:#228822;">Gainers on news:</span></strong><br/> <ul><li>Vertex Pharma (<strong>VRTX</strong> +22.83%) confirms two Phase 3 Studies of the tezacaftor/ivacaftor combination treatment met primary endpoints with statistically significant improvements in lung function in people with cystic fibrosis</li><li>Interpace Diagnostics (<strong>IDXG</strong> +6.16%) traders circulate European patent document for microRNA's as biomarkers for distinguishing benign from malignant thyroid neoplasms</li><li>Tonix Pharma (<strong>TNXP</strong> +41.79%) to Present FDA Breakthrough Therapy-Designated PTSD Program at The MicroCap Conference</li></ul><strong><span style="color:#ff0000;">Decliners on news:</span></strong><br/> <ul><li>Ritter Pharma (<strong>RTTR</strong> -18.97%) announces lactose intolerance treatment RP-G28 demonstrated efficacy and clinically meaningful benefit in phase 2b/3 clinical trial; data supports further clinical development</li><li>DepoMed (<strong>DEPO</strong> -3.83%) announces cooperation agreement with Starboard, names new CEO, sees Q1 revs below consensus</li><li>Alliqua (<strong>ALQA</strong> -32.18%) prices 9.375 mln common stock offering at $0.40/share</li></ul><strong><span style="color:#228822;">Gainers on earnings:</span></strong><br/> <ul><li>Summit Therapeutics (<strong>SMMT</strong> +1%) FY17 EPS ($0.44) vs. ($0.56) consensus; rev $2.9 mln vs. 0.2 mln consensus.</li></ul><strong><span style="color:#ff0000;">Decliners on earnings:</span></strong><br/> <ul><li>Pernix Therapeutics (<strong>PTX</strong> -17.98%) reports Q4 adjusted EBITDA +49% to $12.5 million from $8.4 million in third quarter 2016 and 60% from $7.8 million in the prior year period; revs +3.7% y/y to $45.4 mln (no estimates).</li><li>Quorum (<strong>QHC</strong> -15.23%) reports Q4 (Dec) results, misses on revs</li><li>Delcath (<strong>DCTH</strong> -7.29%) reported FY16 EPS of ($10.59) vs ($14.56) last year.</li></ul><strong>Upgrades/Downgrades:</strong><br/> <ul><li>Athersys (<strong>ATHX</strong> +21.19%) initiated with an Outperform at William Blair</li><li>EXACT Sciences (<strong>EXAS</strong> +5.58%) initiated with a Buy at BofA/Merrill; tgt $29</li><li>Regeneron Pharma (<strong>REGN</strong> +3.64%) UBS Reiterated BUY — Price Target: 446 (from 435)</li><li>Cempra (<strong>CEMP</strong> -3.57%) Gabelli & Co Downgraded to SELL (from Hold)</li></ul>"